A treatment investigational new drug (tIND) program of tegaserod 6 mg bid [twice daily] given orally in women adult patients with irritable bowel syndrome with constipation or with chronic idiopathic constipation

Trial Profile

A treatment investigational new drug (tIND) program of tegaserod 6 mg bid [twice daily] given orally in women adult patients with irritable bowel syndrome with constipation or with chronic idiopathic constipation

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 23 Jan 2008

At a glance

  • Drugs Tegaserod (Primary)
  • Indications Constipation; Irritable bowel syndrome
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 23 Jan 2008 Added status according to nct updated 10 jan 08.
    • 14 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top